Skip to main content

Betarezeptorenblocker

  • Chapter
  • First Online:
Arzneiverordnungs-Report 2021
  • 2997 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Arzneimittelkommission der deutschen Ärzteschaft (2009) 23. Arterielle Hypertonie: Arzneiverordnungen, 22. Aufl. Medizinische Medien Informations GmbH, Neu-Isenburg, S 597–628

    Google Scholar 

  • Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP (2013) Sytematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol 168:3572–3579

    Article  Google Scholar 

  • Bowman AJ, Chen CP, Ford GA (1994) Nitric oxide mediated venodilator effects of nebivolol. Brit J Clin Pharmacol 38:199–204

    Article  CAS  Google Scholar 

  • Chatterjee S, Biondi-Zoccai G, Abbate A, D’Ascenzo F, Castagno D, Van Tassell B, Mukherjee D, Lichstein E (2013) Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 346:f596

    Article  Google Scholar 

  • Chobanian AV et al (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). JAMA 289:2560–2572 (Erratum in: JAMA 2003, 920:197)

    Article  CAS  Google Scholar 

  • CIBIS II Study (1999) The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 353:9–13

    Article  Google Scholar 

  • Gulea C, Zakeri R, Alderman V, Morgan A, Ross J, Quint JK (2021) Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison. Resp Res 22:64. https://doi.org/10.1186/s12931-021-01661-8

    Article  CAS  Google Scholar 

  • Grundt C, Meier K, Grundt A, Lemmer B (2007) Evidence for an estradiol-agonistic action of nebivolol in spontaneously hypertensive rats. J Hypertens 25:1001–1007

    Article  CAS  Google Scholar 

  • Kintscher U, Böhm M, Goss F, Kolloch R, Kreutz R, Schmieder R, Schunkert H (2014) Kommentar zur 2013-ESH/ESC-Leitlinie zum Management der arteriellen Hypertonie. Kardiologie 8:223–230

    Article  CAS  Google Scholar 

  • Léauté-Labrèze C, Hoeger P, Mazereew-Hautier J et al (2015) A randomized, controlled trial of propranolol in infantile hemangioma. N Eng J Med 19:735–746

    Article  Google Scholar 

  • MERIT-HF Study (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 353:2001–2007

    Article  Google Scholar 

  • Moen MD, Wagstaff AJ (2006) Nebivolol – a review of its use in the management of hypertension and chronic heart failure. Drugs 66:1389–1409

    Article  CAS  Google Scholar 

  • Packer M, Coats AJS, Fowler MB, Katus HA et al (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651–1658

    Article  CAS  Google Scholar 

  • POISE Study Group (2008) Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial) a randomized controlled trial. Lancet 371:1839–1847

    Article  Google Scholar 

  • Sackner-Bernstein J (2005) Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy. Clin Cardiol 28(11 Suppl 1):19–27

    Google Scholar 

  • Thomopoulos C, Parati G, Zanchetti A (2015) Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihyperten-sive drugs – overview and meta-analyses. J Hypertens 33:195–211

    Article  CAS  Google Scholar 

  • Tzemos N, Lim PO, MacDonald TM (2001) Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 104:511–514

    Article  CAS  Google Scholar 

  • Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Björn Lemmer .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Der/die Autor(en), exklusiv lizenziert durch Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lemmer, B. (2021). Betarezeptorenblocker. In: Ludwig, WD., Mühlbauer, B., Seifert, R. (eds) Arzneiverordnungs-Report 2021. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-63825-5_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-63825-5_20

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-63824-8

  • Online ISBN: 978-3-662-63825-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics